Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clairleaf long-term extension study of BI 1291583 in bronchiectasis
MOH_2024-01-01_013145Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verducatib in bronchiectasis (3 arms), sponsored by Boehringer Ingelheim. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on MOH_2024-01-01_013145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-01_013145.